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Abstract
Policies are an important part of public health interventions, including in the area of STD 
prevention. Similar to other tools used in public health, policies are often evaluated to determine 
their usefulness. Therefore, we conducted a non-systematic review of policy evidence for sexually 
transmitted disease prevention. Our review considers assessments or evaluations of STD 
prevention-specific policies, health care system policies, and other, broader policies that have the 
potential to impact STD prevention through social determinants of health. We also describe 
potential policy opportunity in these areas. It should be noted that we found gaps in policy 
evidence for some areas; thus, additional research would be useful for public health policy 
interventions for STD prevention.
Short summary
Additional research that assesses or evaluates public health policy interventions for STD 
prevention would be useful.
IMPORTANCE OF POLICY IN PUBLIC HEALTH INCLUDING STD 
PREVENTION
Public health has long recognized the important role that policy –defined as laws, 
regulations, and other administrative actions or practices of governments and other 
institutions – can play in health.[1–3] In 1980, the Institute of Medicine (IOM) cited policy 
development as one of the three core public health functions for governmental agencies,[4] 
and policy interventions were reportedly a factor in each of the 10 major health 
achievements of the last century.[2] Structural interventions, including policies, may be of 
special interest to public health given that they have the potential to reach many individuals 
with less effort and cost than many other interventions.[4] The importance of policies in 
public health was further highlighted in a 2011 IOM report that focused on policy’s role in 
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improving health at a population-level and included several recommendations to 
governmental and public health agencies, including that “government agencies … 
familiarize themselves with the tool box of public health legal and policy interventions at 
their disposal.”[5] Another of the IOM’s recommendations focused on the assessment of 
evidence for existing and new policies and the identification of gaps in policies. Thus, it is 
important to assess and evaluate policies as they can serve as an intervention and can also 
serve in support of other interventions.
Although data has often been used to justify putting new policies into place (e.g., use of 
prevalence and cost-effectiveness data to recommend evidence-based policies), less research 
has focused on evidence related to existing policies for STD prevention in the United States. 
Such policies may serve as either barriers or facilitators to STD prevention. As with other 
STD prevention tools, policies may be evaluated to maximize impact. Thus, the purpose of 
this non-systematic review is to highlight selected research that has focused on 1) the 
assessment of STD-relevant policies and 2) the evaluation of the effectiveness of existing 
policies in STD prevention. Studies did not have to examine all aspects of effectiveness to be 
included. We used Medline/OVID, web searches (gray literature), and input from colleagues 
to compile research related to policy assessment and evaluation for STD prevention that was 
published from 1990-present. To narrow the scope of this review, research that focused 
solely on the need for a given policy was not included. We provide an overview of the policy 
evidence landscape for STD prevention. Additionally, we highlight potential policy 
opportunities that may be useful for future STD prevention efforts. Given the breadth of our 
topic and the challenges in conducting policy evaluations, we do not systematically assess 
the evidence for policies. Rather, we briefly highlight existing research.
Several policies where research has identified an association with STD prevention efforts or 
outcomes are included in this review. First, we describe research on policies specific to STD 
prevention, including policies related to expedited partner therapy (EPT) and to STD 
screening. We also describe where additional evidence to support these and other established 
or novel STD-specific policies would be useful. Next, we highlight recent policy changes in 
the healthcare system and highlight how research could identify potential impacts on STD 
prevention. Finally, we discuss broader policies impacting social determinants of STD risk, 
on issues such as economics, criminal justice, employment and housing.
POLICIES FOCUSED ON STD PREVENTION ISSUES
At a fundamental level, policies are the basis for STD prevention efforts at state and local 
public health departments. A 2013 compendium of state statutes that explicitly focus on 
STDs other than HIV[6] shows that these laws largely focus on the establishment of STD 
programs and/or clinics, mandatory testing and/or treatment, expedited partner therapy, and 
the confidentiality of STD-related records.[7] Additionally, an assessment of state disease 
intervention laws found that most jurisdictions have STD-related disease intervention laws.
[8] However, little is known about the effectiveness of many of these policies in STD 
prevention. Thus, in its funding for STD programs in state health departments, the Centers 
for Disease Control and Prevention (CDC) has emphasized policy activities, including 
assessment and evaluation of policies.[9] In particular, an increased capacity to monitor and 
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evaluate relevant policies and to disseminate information about effective policies is 
anticipated to have an impact on long-term STD prevention outcomes.
Regarding assessment of STD policies, Myerson and colleagues (2003) conducted a survey 
to examine STD program involvement in state policy during 1995 and 2000 (refer to Table 
1).[10] Three-quarters of programs reported involvement in policy activities and these 
activities increased from 1995 to 2000. Specifically, dissemination of STD information to 
policy makers, collaboration with coalitions, and testimony at state legislative hearings were 
policy behaviors that increased, and many activities reported in 1995 were continued in 
2000. Below we highlight evidence from other assessments and evaluations of specific STD 
policies beginning with expedited partner therapy (EPT).
Expedited Partner Therapy (EPT)
EPT, a partner notification strategy that relies on the patient to deliver treatment to partners 
and has been shown to reduce gonorrhea reinfection in randomized controlled trials,[11–12] 
provides an example of the role that policy assessment and evaluation can play in hindering 
or advancing STD prevention efforts. Specifically, one frequently mentioned barrier to 
implementing EPT was provider concern regarding the legality of EPT (i.e., the uncertain 
legal status for EPT and whether providers may have legal liability if they provide treatment 
without a physical examination).[13–14] Thus, Hodge and colleagues[15] examined the 
policy environment for all states (including the District of Columbia and Puerto Rico) 
categorizing EPT in each jurisdiction as permissible, potentially allowable, or likely 
prohibited. Findings suggested that EPT was legally permissible in 12 areas, potentially 
allowable in 28, and likely prohibited in 13 at that time.
Awareness of the policy landscape for EPT, and efforts to change policies that may serve as 
barriers, may be related to the substantive changes that have occurred in EPT policies over 
time. As of August 2014, EPT was permissible in 35 jurisdictions, potentially allowable in 9, 
and likely prohibited in 6.[16] Furthermore, research has provided evidence showing an 
association between supportive EPT policies and increased use of EPT. For example, a 
multi-state study of the relationship between state-level EPT policies (e.g., laws and 
medical/pharmacy board statements) and gonorrhea patients receiving EPT found evidence 
that EPT use is higher in states with policies that are supportive to its use.[17] Additionally, 
an assessment of federally qualified health centers in New York City conducted in 2012 
found that approximately half of governing organizations had written policies permitting 
EPT.[18] Of clinical sites examined, 80% provided EPT with slightly more use (86%) at 
sites whose governing organization had a written EPT policy.[18] Finally, a policy change 
that included EPT documentation in electronic medical records was associated with an 
increase in EPT from 20 to 48% for patients with chlamydia or gonorrhea.[19]
Although changes in EPT policies have been promising, some policy barriers remain. For 
example, a study of family planning providers indicated that reimbursement issues from 
health insurance plans remain a significant barrier to EPT.[20] This barrier remained even 
though another study found EPT to be cost-effective from a health systems perspective; for a 
given health insurance plan, EPT was less costly than standard partner referral when 
approximately one-third or more of partners were on the plan.[21]
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Multiple studies have sought to assess or evaluate STD screening policies, often with regard 
to specific topics or settings. Additionally, several studies focus on cost-effectiveness of 
screening in a given subpopulation to provide evidence in support of a policy. However, less 
research has assessed how often these policies exist in various healthcare delivery settings 
and at different levels including governmental and other institutions. For example, one study 
assessed prenatal screening laws for syphilis at the state-level;[22] such screening is 
recommended by the CDC and various medical groups.[ 22–23] The study found that the 
vast majority of jurisdictions (90%) had laws that required syphilis screening during 
pregnancy or at delivery. Additionally, findings suggested that states lacking these laws were 
not high morbidity areas, and the laws varied in the number and timing of screening 
required.[22] In another example, a 1997 assessment of STD testing policies in jail settings 
found that few facilities had policies to offer routine screening.[24] Rather, policies focused 
on testing detainees who had symptoms or who requested testing only.[24] However, 
facilities that reported following CDC guidelines were significantly more likely to have a 
policy to screen women for chlamydia.[24] Both studies suggest that awareness of STD rates 
or guidelines may be related to STD policies; however, the assessments were conducted over 
a decade ago and policies may have changed subsequently. Finally, although assessments of 
existing screening policies are important, they do not demonstrate whether these policies are 
effective.
Therefore, research has also evaluated STD screening policies to determine their impact and 
any remaining policy barriers. For example, HEDIS (Healthcare Effectiveness Data and 
Information Set) measures performance of health plans (private and public) on key aspects 
of healthcare including screening. One study evaluated the impact of a HEDIS performance 
measure focusing on chlamydia screening of sexually active young women as a new 
measure for health plans.[25] In one health plan, after introduction of the measure, screening 
of eligible women increased from 55% in 1998–99 to 72% in 2000–01 (p<.001).[25] In 
correctional settings, a few studies have evaluated screening policies. Two studies of jail 
screening policies provide some evidence of effectiveness for these policies. A study in San 
Francisco found that a higher jail testing density was associated with a decrease in 
chlamydia positivity in a clinic in that community; conversely, prevalence was stable at a 
clinic with a lower jail testing density in the community.[26] After screening policy was 
discontinued at a jail, another study found a decline in reported chlamydia and gonorrhea 
cases in a community.[27] The authors speculate that the reduction in screening may have 
led to undiagnosed cases.[27] Conversely, a separate study of a prison male screening policy 
in Philadelphia found that chlamydia positivity among 20–24 year old women declined in 
areas with high and low screening.[28] Thus, additional research is needed to fully evaluate 
the impact of screening policies on testing rates and on community prevalence.
Research evaluating changes in screening policies underscore the need for policy changes to 
be communicated and implemented effectively. Subsequent to national recommendations for 
chlamydia screening, various interventions have attempted to increase awareness of this 
policy. For example, chlamydia screening increased 14% among private providers in two 
counties of Michigan.[29] Similarly, screening rates also increased in three private providers 
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offices after tools and training were provided.[30] An evaluation of the HEDIS chlamydia 
measure among providers in Hawaii found that a lack of awareness of reimbursement for 
screening was a barrier to following the recommendation.[31] Finally, it is possible that 
some policy changes do not have an impact on screening. For instance, changes in insurance 
coverage for chlamydia screening in two states did not appear to impact screening rates [32]; 
and, syphilis screening among pregnant women has remained low even in an area of high 
incidence.[33] More research is needed to fully examine the impact of these policies on 
uptake of recommended screening services.
Other STD-specific Policy Opportunities
Finally, other aspects of STD prevention (e.g., beyond EPT and screening) appear to have 
less of an evidence base for various policies; however, we highlight areas where research has 
been conducted and where new policy opportunities may exist. For example, research 
conducted in the early 1980s examined mandated premarital syphilis testing policies found 
that such testing yielded few positive tests and state health officers favored their elimination. 
[34] Subsequent to such research, few of these laws remain. Thus, it is important to 
demonstrate a given policy’s effectiveness as a population-based strategy to: 1) assess 
policies that may be unnecessary and 2) reduce future policies that are not useful. 
Conversely, policy efforts, particularly regarding public health collaboration with the private 
sector, may be useful for STD prevention. For instance, Los Angeles passed legislation 
requiring adult film companies to use condoms in their films. Subsequent to this policy 
change, one study analyzed condom use during adult films and found that condoms were 
used 80% of the time in same-sex anal sex but only 10% and 42% of the time for 
heterosexual anal and vaginal sex, respectively.[ 35] Similarly, state or local policies may be 
considered to support STD prevention in commercial venues, such as bathhouses and sex 
clubs, or risks associated with websites and apps that facilitate 'hooking up.' One study of 
cities with differing policies on bathhouses found that risky sexual behavior occurred at the 
same frequency but in different settings within the bathhouses (public vs. private) in the 
cities.[36] Policy approaches could potentially be used to align business and public health 
interests to create conditions in which people can be healthy, including on the internet. 
However, research is needed to assess current policies and to evaluate whether new or 
revised policies in these areas may aid STD prevention efforts.
POLICIES IN A CHANGING HEALTHCARE SYSTEM THAT MAY IMPACT STD 
PREVENTION
Affordable Care Act and Similar Health System Transformations
The Affordable Care Act (ACA) contains a number of provisions with significant 
implications for STD prevention, including increased access to health insurance and 
requirements for coverage of STD-related preventive services. ACA expands access to both 
public insurance (states that expand Medicaid eligibility to all nonelderly adults living below 
133% of the federal poverty level only) and private health insurance (through subsidies and 
option of staying on parents’ plan until age 26 years).[37–41] Additionally, all new 
individual and small groups plans, as well as all plans for people newly covered under the 
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Medicaid expansion, must cover ten categories of “Essential Health Benefits,” that include 
STD-relevant services such as ambulatory patient services; maternity and newborn care; 
prescription drugs; and preventive and wellness services.[38–39] In addition, all new private 
plans – individual, small group, and employer – as well as Medicaid “expansion” coverage, 
must cover without cost-sharing (i.e., co-pays) all Grade A and B preventive services 
recommended by the U.S. Preventive Services Task Force (USPSTF), the CDC’s Advisory 
Committee on Immunization Practices (ACIP), and, with regard to children and women, the 
Health Resources and Services Administration (refer to Table 2 for a list of services).[40] 
Pre-expansion Medicaid programs are not required to cover these services but ACA provides 
an incentive to cover the USPSTF and ACIP recommendations without cost-sharing.[41–42] 
The Affordable Care Act also promotes access to “Essential Community Providers” that 
serve primarily low-income, underserved populations, including STD clinics.[42] Thus, 
there are many potential routes for the ACA to intersect with STD prevention.
Although it is too early to evaluate the full effects of the ACA, some have tried to anticipate 
its impact on STD services, including a recent paper that highlights potential impacts on 
chlamydia screening.[43] Others have highlighted the continued need for safety net services 
for persons who remain uninsured or who seek STD services from safety net providers for 
reasons related to confidentiality and timeliness and quality of care.[44–45] Studies from 
Massachusetts, where some similar healthcare system reforms were implemented in 2006, 
may highlight the potential impact and remaining barriers to accessing sexual health services 
in a changing healthcare environment (refer to Table 3). An evaluation of the impact of 
Massachusetts reforms on adults aged 19–64 years found an increase in insurance coverage 
from 87% in 2006 to 94% in 2010.[46] Also during this time, reported access to and use of 
health care services increased by 5% for having a usual place for care and by 6% for having 
a preventive service visit.[46] Further, a Massachusetts study evaluated the effect of health 
reforms and the subsequent implementation of a $75 fee for STD visits following the 
elimination of public funding for STD services in 2009.[47] They found that STD patient 
visits decreased overall; however, service patterns differed with significant decreases at the 
STD clinic but increases in STD diagnoses during primary care visits.[47] It remains to be 
seen the extent to which the experience in Massachusetts will predict the impact of the ACA 
on a national level.
Third-party Billing
Higher rates of health insurance coverage, mandates for coverage of preventive services, and 
the opportunity to contract with more health plans may translate into incentives for STD 
clinics to develop or enhance third-party billing systems. Facing funding shortages, Kansas 
developed a coordinated approach to third-party billing using 6 regional billing groups.[48] 
Subsequent to the provision of training and technical assistance to the billing groups, 
reimbursements increased by 50–75% among local health departments.[48] An assessment 
of billing among STD clinics found that 30% of clinics were billing public insurance only 
and 45% were billing both public and private insurance.[49] Clinics reported numerous 
barriers to third party billing;[49] thus, a toolkit to aid in billing and reimbursement was 
developed.[50] Finally, a policy assessment examined several potential policy barriers to 
third-party billing in state statutes.[51] Although there are some potential policy barriers to 
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billing, there are several possibilities to lessen their impact. For example, eight states have 
statutes requiring health departments to provide free STD services;[51] however, health 
department attorneys in one of the eight states (Pennsylvania) determined that the statute did 
not prohibit billing insurance when available (e.g., patients’ can be asked to voluntarily 
provide their health insurance information).[52]
Access to Confidential STD Services
Given increased expansion of health insurance and the accompanying health insurance plan 
communications with insured, an issue of heightened importance in the changing healthcare 
system is maintaining access to confidential STD services, particularly for adolescents and 
young adults. Access to confidential services among adolescents has long been identified as 
a significant issue.[53] Studies have shown that adolescents and young adults may avoid or 
delay seeking healthcare for sensitive services to ensure that their illness remains private 
(i.e., their regular doctor or parent won’t know).[54] A significant percentage of insured 
women who attend family planning clinics did not want to use their insurance to minimize 
potential disclosure of their health information.[55–56] There are two legal issues related to 
accessing STD services: 1) laws that allow minors to consent for STD services and 2) laws 
that protect confidentiality of health insurance communications. Guttmacher[57] found that 
all states have laws allowing minors to consent for STD services; however, the age of 
consent varies and 18 states permit the provider to disclose the service to parents. Further, a 
review of state confidentiality laws and policies for insured dependents found that many 
states have laws requiring that certain health communications be sent to the insured (e.g., 
explanation of benefits).[58] These policies may have a specific impact on use of healthcare 
services among adolescents and young adults who are dependents on their parents’ 
insurance plans, as ACA extends this coverage up to age 26 years. As safety net providers 
also often serve as providers of confidential services, it is important to consider how to best 
maintain these necessary services.[45]
BROADER POLICIES THAT MAY IMPACT STD PREVENTION
There are many other policies that do not directly focus on STD prevention but may 
indirectly impact it. These policies include but are not limited to policies related to other 
public health issues, social determinants of health (including policies in areas such as 
economics, education, housing, and criminal justice), comprehensive sex education, and 
health professionals’ scope of work. Previous research has highlighted evaluations that 
provide some evidence for a few of these policies role in STD prevention. In a non-
systematic review, Chesson examined various economic policies that have been associated 
with STD.[59] For example, research has suggested an association between welfare policies 
and STD in that higher welfare payments were associated with higher STD rates. Two 
studies have found that alcohol taxes had an inverse relationship with STDs, particularly for 
gonorrhea among men (e.g., higher taxes may lower gonorrhea rates).[59] Additionally, 
another study found that alcohol taxes and zero-tolerance laws were associated with 
decreased gonorrhea in young men; however, no evidence was found to support blood 
alcohol content or dry county laws.[60] Other alcohol policies have been associated with 
STD prevalence; alcohol availability has been associated with gonorrhea in two studies.[59] 
Leichliter et al. Page 7













However, like many policy evaluations, these studies were unable to demonstrate a causal 
relationship between the general policies and STD prevention.
Finally, legislators frequently propose laws that may affect upstream determinants of STDs, 
such as policies related to poverty, the criminal justice system, or education. For example, 
research has shown that incarceration is related to STD and may disrupt sexual networks and 
sex ratios in a community.[61–62] Additionally, issues such as housing policy changes that 
disperse residents from public housing complexes into different communities can impact 
STD prevention. One evaluation of a related policy in Atlanta found that STD prevalence 
and some sexual risk behaviors decreased after residents were moved away from public 
complexes.[63] However, like many policy evaluations, this study was unable to demonstrate 
a causal relationship between the general policies and STD prevention. Additionally, other 
research has described how a Health in All Policies approach (e.g., systematic consideration 
of health outcomes in all decision making processes)[64] can be used to address social 
determinants of health often associated with STD in relation to redevelopment policies.[65] 
Thus, it may be beneficial for STD programs to consider the potential impact of legislation 
on STD prevention in their jurisdiction. This focus can also have the added benefit of 
forging coalitions between different constituencies, and bringing a greater spotlight to STD 
related issues. Government employees often face restrictions preventing them from 
contacting policymakers with regard to specific legislation or actions. However, they can 
usually provide educational information to policymakers as well as to their partners.
CONCLUSION
We identified several STD-specific, healthcare system, and general policies that have been 
associated with STD prevention and public health in research. Depending on local 
epidemiology, many of the policies that we have highlighted may be of interest to STD 
programs in state and local health departments, as well as public health researchers and 
practitioners. Such policies could be included as one type of intervention to be considered 
for STD prevention efforts. Specifically, we found associations between policies and areas of 
STD prevention such as EPT and STD screening. However, in some instances, additional 
evidence to support these policies would be useful. Also, we highlight recent changes in the 
healthcare system and potential impacts on STD prevention. Finally, our review has also 
identified some gaps in research focusing on the effectiveness of some policies. There are 
numerous other policies including socioeconomic, criminal justice, and in other areas such 
as employment and housing, that may influence STD prevention efforts. Research is needed 
to evaluate their relationship with STD morbidity. Furthermore, it should be noted that laws 
and policies must be implemented and/or enforced to impact STD prevention. We identified 
some instances (e.g., EPT and prenatal syphilis screening policies) where efforts are needed 
to disseminate these policies in order to increase uptake.
There are difficulties in evaluating many public health strategies, and randomized controlled 
trials often are not feasible.[66] These difficulties are often heightened for policy evaluations 
as “linkages between … policy and actual health outcomes may be extraordinarily difficult 
to specify.”[66] Also, it can be especially difficult to evaluate policies given that the 
selection and measurement of outcomes, often at a community-level, can be challenging. 
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Garfinkel and colleagues[67] argue that the use of mapping can aid in the understanding of 
the roles that health research and policies may play for a given health outcome. Thus, our 
finding of limited evidence of a relationship between general policies and STD prevention in 
the context of policy evaluation was not unexpected. Rather, these findings highlight the 
difficulties in evaluating policies in “real-world” settings. In this context, multiple ecological 
or observational studies can and have been used to provide evidence in many fields.[68]
The gaps that we identified highlight the need for further research (including policy 
assessments and evaluations) into policies and STD prevention as policies have the potential 
to reach many individuals at a low cost. Like any other tool in the STD prevention toolbox, 
the use of policy interventions specifically for STD prevention must be evaluated so that 
STD programs and others can implement policies that work. For policies addressing the 
broader healthcare system or social determinants, STD programs must be aware of the 
opportunities and challenges created for STD prevention. The IOM has recommended a 
focus on policies to improve public health,[5] and others have argued that it is important for 
state and local health departments to improve policy assessment.[69] It is important to note 
that legal and policy barriers do not always require a legal/policy solution; policy 
interventions do not have to rely on legislation in order to be successful. Many of the same 
tools used in policy development – building constituencies, obtaining the support of key 
stakeholders, and developing common standards and guidelines – can be beneficial. 
Additionally, many healthcare institutions have policies that are easier to change than 
policies that require legislation and will still likely influence the health of their clients.
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• Policies are an important part of public health, and have the potential to 
impact many individuals at a relatively low cost.
• Research on STD prevention-specific policies has largely focused on EPT and 
various screening policies.
• Recent healthcare system changes may intersect with STD screening policies 
and other STD prevention issues.
• Assessments and evaluations of policies are essential; more research is needed 
to evaluate the role of policies in STD prevention.
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Table 2
STD services covered without cost sharing under ACA
STD Services Listed as USPSTF Recommended (Grade A and B) Services as of Sept 20141
• Chlamydia screening: women – screen sexually active women age 24 years or younger and in older women who are at increased 
risk for infection
• Gonorrhea screening: women -- screen sexually active women age 24 years or younger and in older women who are at increased 
risk for infection
• Gonorrhea prophylactic medication: newborns – recommends prophylactic ocular topical medication for all newborns for the 
prevention of gonococcal ophthalmia neonatorum
• Cervical cancer screening; women ages 21 to 65 years – screen with cytology (Pap smear) every 3 years, or for women ages 30 to 
65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus 
(HPV) testing every 5 years
• Sexually transmitted infections counseling: intensive behavioral counseling for all sexually active adolescents and for adults who 
are at increased risk for sexually transmitted infections.
• Syphilis screening: nonpregnant persons – screen persons increased risk for syphilis infection
• Syphilis screening: pregnant women – screen all pregnant women for syphilis infection
ACIP Vaccine Recommendations2
• routine HPV2 or HPV4 vaccination of females aged 11 or 12 years, and catch-up vaccination for females aged 13 through 26 
years
• routine HPV4 vaccination of males aged 11 or 12, and catch-up for males aged 13 through 21
Bright Futures (AAP and HRSA)3
• STI screening for all sexually active 11–21 year olds
• Screening for cervical dysplasia in all sexually active girls as part of a pelvic exam beginning within 3 years of onset of sexual 
activity or at age 21, whichever comes first
HRSA Women’s Preventive Services4
• Annual STI counseling for all sexually active women
• High-risk HPV DNA testing in women with normal cytology results, beginning at 30 years of age and occurring no more 
frequently than every 3 years
Note: there is some overlap in the USPSTF and HRSA recommendations. USPSTF = U.S. Preventive Services Task Force. ACIP = Advisory 
Committee for Immunization Practices. AAP = American Academy of Pediatrics. HRSA = Health Resources and Services Administration.
1
USPSTF A and B recommendations available at: http://www.uspreventiveservicestaskforce.org/uspstf/uspsabrecs.htm.
2




HRSA guidelines for women available at: http://www.hrsa.gov/womensguidelines/#footnote
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